Corporate news

to the archive

Dermapharm Holding SE with increased free float

Grünwald, July 1, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft (“Themis”) that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.

The 580,000 shares are from the agreed Greenshoe option. Themis had acquired these shares after the flotation on February 9, 2018 to stabilize the price.

Following the sale, the shareholder structure is now composed as follows: At 75.05% (previously 76.13%), the majority of the no-par shares continue to be held by Themis. 24.95% (previously 23.87%) of the shares of Dermapharm are in free float.

For the time being Dermapharm expects that Themis will not further reduce its share in Dermapharm.

Michael Diegelmann

Newsletter subscription

Contact

+49 611 205 855 0

(Mon. - Fri. 09.00 - 18.00)

Answer Mon. - Fri.

within 24 hours

Newsletter subscription

Including a free extract of our bestseller book

Michael Diegelmann
Henryk_Deter

Newsletter subscription

Contact

+49 611 205 855 0

(Mon. – Fri. 09.00 – 18.00)

Answer Mon. – Fri.

within 24 hours

Newsletter subscription

Including a free extract of our bestseller book